搜索
BullFrog AI Holdings, Inc.
BFRG添加自选
0.591USD
-0.025-3.99%
收盘 05/15, 16:00（美东）报价延迟15分钟
10.96M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.99%
5天
-10.41%
1月
-45.25%
6月
-40.86%
今年开始到现在
-33.02%
1年
-66.21%
TradingKey BullFrog AI Holdings, Inc.股票评分
单位: USD 更新时间: 2026-05-15操作建议
BullFrog AI Holdings, Inc.当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名199/382位。机构持股占比非常高，中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
BullFrog AI Holdings, Inc.评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
BullFrog AI Holdings, Inc.亮点
亮点风险
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
业绩高增长
公司营业收入稳步增长，连续3年增长79.49%
业绩增长期
公司处于发展阶段，最新年度总收入116.67K美元
利润高增长
公司净利润处于行业前列，最新年度总收入116.67K美元
估值高估
公司最新PE估值-1.09，处于3年历史高位
机构减仓
最新机构持股629.79K股，环比减少48.62%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.71
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BullFrog AI Holdings, Inc.新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BullFrog AI Holdings, Inc.简介
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
公司代码BFRG
公司BullFrog AI Holdings, Inc.
CEOSingh (Vininder)
网址https://www.bullfrogai.com
相关品种
